Application Note No. 62 Analysis of Pharmaceuticals’ Impurity - Regulations and Analysis for Carcinogenic Substances Dheeraj Handique *a), Nitish Suryawanshi *a), Crystal Yeong *b), Cynthia Lahey *b), Shailendra Rane *a), Deepti Bhandarkar *a), Anant Lohar *a), Gao Jie san *c),…
Key words
ndma, ndea, carcinogenic, substances, mutagenic, mms, ems, impurity, mode, ims, mutagenicity, drug, olmesartan, ndba, headspace